Advertisement

Topics

Circassia Moves Away from a Failed Allergy Pipeline with Phase III Success

05:31 EDT 7 Sep 2017 | Labiotech.eu

Circassia has positive Phase III results from its respiratory pipeline, great news for the company after abandoning its allergy immunotherapies due to clinical failure. Circassia Pharmaceuticals, based in Oxford, has reported a Phase III success with Duaklir, a drug combination ...

This awesome article Circassia Moves Away from a Failed Allergy Pipeline with Phase III Success appeared first on Labiotech.eu. Be kind and don't copy it without asking ;)

Original Article: Circassia Moves Away from a Failed Allergy Pipeline with Phase III Success

NEXT ARTICLE

More From BioPortfolio on "Circassia Moves Away from a Failed Allergy Pipeline with Phase III Success"

Quick Search
Advertisement
 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Respiratory
Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs.  They're usually caused by viruses, but they can also ...

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...